Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

University of Toronto

$157,999.00

Development and Testing of Small Molecule Allosteric Modulators for the Treatment of Pain.

FY 2012-13

Summary
The body contains receptors which are activated by compounds called 'cannabinoids'. These are called cannabinoid CB1 and CB2 receptors. Cannabinoids called 'endocannabinoids' are produced in the tissues where they interact with cannabinoid receptors to modulate physiological responses. Endocannabinoids are involved in leaning and memory, appetite stimulation, pain processing and mood. The levels of these compounds in the body increase in certain diseases where they act to relieve symptoms. Compounds which inhibit the enzymatic breakdown of the endocannabinoids are being tested in clinical trials for the treatment of pain, depression and anxiety. Activators or 'agonists' of the CB1 receptor are not ideal as drugs because they produced unwanted psychoactive side-effects. We have discovered compounds which act in such a way that they do not activate the CB1 receptor, but rather enhance the effects of the endocannabinoids. In this application we will modify the chemical nature of this compound to make it a better drug and we will investigate the effectiveness of the compound as a new therapeutic treatment for various types of pain.
Program
Proof of Principle Program - Phase I
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
268518
Name
Ross Ruth A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development and Testing of Small Molecule Allosteric Modulators for the Treatment of Pain.
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$157,999
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Allosteric; Cannabinoid; Drug Discovery; Pain
Abstract
The body contains receptors which are activated by compounds called 'cannabinoids'. These are called cannabinoid CB1 and CB2 receptors. Cannabinoids called 'endocannabinoids' are produced in the tissues where they interact with cannabinoid receptors to modulate physiological responses. Endocannabinoids are involved in leaning and memory, appetite stimulation, pain processing and mood. The levels of these compounds in the body increase in certain diseases where they act to relieve symptoms. Compounds which inhibit the enzymatic breakdown of the endocannabinoids are being tested in clinical trials for the treatment of pain, depression and anxiety. Activators or 'agonists' of the CB1 receptor are not ideal as drugs because they produced unwanted psychoactive side-effects. We have discovered compounds which act in such a way that they do not activate the CB1 receptor, but rather enhance the effects of the endocannabinoids. In this application we will modify the chemical nature of this compound to make it a better drug and we will investigate the effectiveness of the compound as a new therapeutic treatment for various types of pain.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ross, Ruth A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $157,999~ $0~